It may be safe to omit stenting in some STEMI patients who have adequate flow restored and minimal residual stenosis, according to a look back at data from the DANAMI3-DEFER trial. Yet researchers ...

Studies served up a slew of data at the virtual TCT Connect conference on ditching aspirin sooner after ST-segment myocardial infarction (STEMI); stroke risk with different transcatheter aortic valves ...

". . . the SESAMI results are encouraging and provide further proof of the safety of sirolimus-eluting stents in STEMI patients. Such findings are likely to add to the growing list of available ...

The current debate in cardiology centers on the use of drug-eluting balloons (DEBs) vs drug-eluting stents (DESs) in de novo lesions. However, to reach this conclusion, it must be shown that the ...

CHICAGO – Compared with a bare-metal stent, the use of a stent with a biodegradable polymer that releases the drug biolimus resulted in a lower rate of major adverse cardiac events at 1 year among ...

Data from the Recently Published GENIA Study Show that Genous Is Associated with Low Rates of Stent Thrombosis and Target Lesion Revascularization HONG KONG, OrbusNeich today reported clinical data ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. After STEMI, a biodegradable polymer sirolimus-eluting ...

For patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease, 10-year data from the DANAMI-3-PRIMULTI trial brought greater assurance that complete revascularization ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “The mortality benefit of bivalirudin in STEMI patients ...

Bare-metal stent implantation with abciximab pretreatment is a recommended reperfusion strategy for acute ST-segment elevation myocardial infarction (STEMI). Although sirolimus-eluting stents reduce ...